- In March 2025, IFF expanded its animal nutrition portfolio by launching Enviva® PRO, a three-strain Bacillus probiotic formulated specifically for swine. Tailored to support piglet gut health during the vulnerable weaning and post-weaning phases, the probiotic helps mitigate challenges such as nutritional stress, digestive issues, and growth setbacks. Backed by extensive research, Enviva PRO demonstrated a 2.5% improvement in average daily weight gain and a 6.3% reduction in diarrhea frequency. Already proven in poultry, this extension underscores IFF’s commitment to targeted, science-driven solutions that enhance livestock welfare, performance, and sustainability across life stages
- In October 2024, Lallemand Animal Nutrition and the Micalis Institute (INRAE, AgroParisTech, Université Paris-Saclay) launched the Biofilm1Health joint laboratory to advance research on beneficial microbial biofilms. This initiative focuses on exploring microbial communities to enhance animal health and develop environmentally sustainable solutions. By integrating high-throughput biofilm phenotyping and AI-driven tools, the collaboration aims to reduce chemical inputs and improve livestock welfare. The project reflects Lallemand’s strong commitment to R&D in microbial innovation, bridging fundamental science with real-world applications in animal nutrition and ecosystem health
- In October 2024, Lesaffre, a global leader in fermentation and yeast-based solutions, acquired a 70% stake in BiOrigin, a Brazilian subsidiary of Zilor, to strengthen its capabilities in producing yeast derivatives for both human food and animal nutrition. This strategic acquisition enhances Lesaffre’s ability to meet the rising global demand for natural, sustainable ingredients, particularly in the savory ingredients and feed yeast markets. BiOrigin’s production facility in Quatá, São Paulo, offers access to abundant local resources such as sugar and renewable energy, aligning with Lesaffre’s sustainability goals and expanding its global manufacturing footprint
- In January 2024, Novozymes A/S and Chr. Hansen Holding A/S officially completed their merger, forming a new global biosolutions leader named Novonesis. This strategic union combines deep expertise in enzymes, microbial solutions, and probiotic yeast technologies, significantly strengthening the company’s presence in the feed and nutrition markets. The merger is expected to unlock substantial sales synergies, accelerate innovation, and expand the portfolio of targeted microbial solutions for animal health and performance. With a shared commitment to sustainability and science-driven development, Novonesis is poised to deliver transformative solutions across the biosolutions value chain
- In January 2024, BIO-CAT, Inc. partnered with Caldic North America to introduce its proprietary probiotic strains and the OPTIFEED ingredient brand to the North American companion animal nutrition market. This collaboration leverages BIO-CAT’s expertise in enzyme and microbial formulations and Caldic’s strong distribution network to deliver customizable, high-performance solutions for pet food and health. The OPTIFEED line, developed at BIO-CAT’s FDA-registered, SQF-certified fermentation facility, is designed to support digestive and gastrointestinal health in pets. The partnership enhances Caldic’s portfolio with innovative ingredients that align with the growing demand for nutritionally advanced pet products
